We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prolactin =1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy.
- Authors
Daham Kim; Cheol Ryong Ku; Kyungwon Kim; Hyein Jung; Eun Jig Lee
- Abstract
Objective: The association between prolactin level variation and prolacti noma size reduction remains unclear. This study aimed to determine the prolactin level cut-off predictive of a tumor size reduction. Design: Retrospective cohort study. Methods: We reviewed medical records of patients with prolactinoma who received primary cabergoline therapy and for whom complete data on pituitary hormone assays and sellar M RI at baseline and 3 months post treatment were available. We tested whether the certain prolactin level after 3 months post treatment predicted better response. Results: Prolactin levels normalized in 109 (88.6%) of 123 included mac roprolactinoma patients. The mean tumor size reduction was 22.9%, and patients in the lowest prolactin tertile (.0.7) had the highest frequency of tumor size reductions of .20% (73.7 vs 52.9% and 45.9% in tertiles 2 (>0.7 to 2.6) and 3 (>2.6 to 20), P = 0.015). Patients with prolactin levels .1 ng/mL exhibited larger tumor size reductions vs those with pr olactin levels of 1.20 (27.2 ± 18.3% vs 19.5 ± 13.9%, P = 0.014), 1.10 (19.3 ± 13.7%, P = 0.017) and 1.5 ng/mL (19.2 ± 14.3%, P = 0.039). A multivariable logistic regression analysis revealed that a prolactin level .1 ng/mL at 3 months and high-dose cabergoline therapy were significantly associated with tumor size reductions of .20% (odds ratio (OR): 2.8, 95% confidence interval (CI): 1.2.6.7, P = 0.017; OR: 2.0, 95% CI: 1.0.3.9, P = 0.043). Conclusions: A prolactin level =1 ng/mL at 3 months after cabergoline treatment was correlated with a significant tumor size reduction in patients with macroprolactinoma. This fi nding may help clinical decision making when treating macroprolactinoma patients.
- Subjects
PROLACTINOMA; PROLACTIN; PITUITARY hormones; CABERGOLINE
- Publication
European Journal of Endocrinology, 2020, Vol 182, Issue 2, p177
- ISSN
0804-4643
- Publication type
Article
- DOI
10.1530/EJE-19-0753